Literature DB >> 22290284

Hematological cancer: Localized non-bulky Hodgkin lymphoma--future questions.

Bertrand Coiffier, Olivier Casasnovas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22290284     DOI： 10.1038/nrclinonc.2012.7

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

Review 1.  Late effects in the era of modern therapy for Hodgkin lymphoma.

Authors:  David C Hodgson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.

Authors:  Ralph M Meyer; Mary K Gospodarowicz; Joseph M Connors; Robert G Pearcey; Woodrow A Wells; Jane N Winter; Sandra J Horning; A Rashid Dar; Chaim Shustik; Douglas A Stewart; Michael Crump; Marina S Djurfeldt; Bingshu E Chen; Lois E Shepherd
Journal:  N Engl J Med       Date:  2011-12-11       Impact factor: 91.245

3.  Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease.

Authors:  David J Straus; Carol S Portlock; Jing Qin; Jane Myers; Andrew D Zelenetz; Craig Moskowitz; Ariela Noy; André Goy; Joachim Yahalom
Journal:  Blood       Date:  2004-08-17       Impact factor: 22.113

4.  Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study.

Authors:  Anthony J Swerdlow; Craig D Higgins; Paul Smith; David Cunningham; Barry W Hancock; Alan Horwich; Peter J Hoskin; T Andrew Lister; John A Radford; Ama Z S Rohatiner; David C Linch
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

Review 5.  Early-stage Hodgkin's lymphoma.

Authors:  James O Armitage
Journal:  N Engl J Med       Date:  2010-08-12       Impact factor: 91.245

6.  Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

Authors:  Andreas Engert; Annette Plütschow; Hans Theodor Eich; Andreas Lohri; Bernd Dörken; Peter Borchmann; Bernhard Berger; Richard Greil; Kay C Willborn; Martin Wilhelm; Jürgen Debus; Michael J Eble; Martin Sökler; Antony Ho; Andreas Rank; Arnold Ganser; Lorenz Trümper; Carsten Bokemeyer; Hartmut Kirchner; Jörg Schubert; Zdenek Král; Michael Fuchs; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Volker Diehl
Journal:  N Engl J Med       Date:  2010-08-12       Impact factor: 91.245

7.  Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.

Authors:  Ralph M Meyer; Mary K Gospodarowicz; Joseph M Connors; Robert G Pearcey; Andrea Bezjak; Woodrow A Wells; Bruce F Burns; Jane N Winter; Sandra J Horning; A Rashid Dar; Marina S Djurfeldt; Keyue Ding; Lois E Shepherd
Journal:  J Clin Oncol       Date:  2005-04-18       Impact factor: 44.544

8.  Long-term cause-specific mortality of patients treated for Hodgkin's disease.

Authors:  Berthe M P Aleman; Alexandra W van den Belt-Dusebout; Willem J Klokman; Mars B Van't Veer; Harry Bartelink; Flora E van Leeuwen
Journal:  J Clin Oncol       Date:  2003-07-28       Impact factor: 44.544
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.